Large-Scale Clinical Trial SHARP to Assess Impact of Personalized Therapy on Biological Aging
Sheba Medical Center has begun recruiting 1,500 volunteers over age 50 for the randomized SHARP trial (data from ClinicalTrials.gov as of May 19, 2026). The project will test whether an individualized health and behavior program, controlled via an app, can slow the biological clock of aging and improve cognitive function over 12 months.
SHARP is not just another longevity clinical trial. It is a strategic maneuver by Israel to capture the global market for validating healthspan interventions. When entry NCT07596576 appeared on ClinicalTrials.gov on May 19, 2026, an attentive observer should have noticed not "1,500 volunteers over age 50" but a trial architecture perfectly designed to generate regulatory-grade data for commercializing aging clocks. Behind the project are individuals whose names are already linked to commercial AI platforms for assessing biological age, and this is no coincidence.
The Essence: Not Studying Aging, but Creating a Market
SHARP's true goal is to set a precedent. No one in the world has yet conducted a randomized controlled trial with n=1500 where the primary endpoint is a change in epigenetic biological age based on DNA methylation. Yes, epigenetic clocks are used in observational studies. But regulators—FDA and EMA—still do not recognize "rejuvenation of epigenetic clocks" as a validated surrogate marker for therapy approval. SHARP aims to change that.
Sheba Medical Center is the ideal venue for this. It is not a private clinic from Silicon Valley but the largest public medical center in the Middle East, ranked in the top 10 global hospitals by Newsweek for four consecutive years. The center's director, Tzipi Strauss, heads neonatology—a person with an impeccable reputation in mainstream medicine. When SHARP data emerges from Sheba, no regulator can say "this was done by some biohacking startup without clinical expertise."
Timeline: Long Preparation Before the Leap
The trial start date is listed as March 1, 2024. This is significant: recruitment has been ongoing for over two years, yet public registration on ClinicalTrials.gov only happened now. Why? Because interim data already exists, and it appears convincing enough to attract partners for the next phase of commercialization.
In parallel, the team has been methodically publishing validation studies. In March 2026, a paper on a cardiovascular biological age clock based on portable ultrasound appeared in the European Heart Journal – Digital Health. The sample was 243 SHARP participants. Key finding: ultrasound age ≥ chronological age by 2 years correlates with metabolic syndrome, even when routine ultrasound shows no pathology. This is product-market fit: the technology detects deviations invisible to standard diagnostics.
Another publication, in Geromedicine from February 2026, features Evelyn Bischof and co-authors describing the integration of AI into clinical longevity management. Bischof is a co-Principal Investigator of SHARP and simultaneously Chief Physician at the Sheba Longevity Center. This is not academic interest. It is a product roadmap.
Who Wins and Who Loses
The winners are obvious. First and foremost, Aisap.ai, an Israeli AI startup listed in the affiliations of the ultrasound validation work. Their algorithm for processing POCUS images is already gaining clinical evidence within a large RCT. A startup that enters a major trial with a validated endpoint is valued three times higher by investors than one with only retrospective data. If SHARP shows a statistically significant slowing of epigenetic age, Aisap.ai's valuation could exceed $400 million.
The second group of winners are insurance companies and health systems seeking risk stratification tools. If a biological age clock can predict hospitalization 3–5 years before the event, annual premium calculation is completely overhauled. Currently, annual elderly care costs in the US are about $50 billion for Medicare Advantage alone. A system that shifts intervention to the preclinical stage saves $10,000–15,000 per patient per year.
The losers are biohacker clinics selling epigenetic age tests for $300–500 without an evidence base. When Sheba publishes results with Level A evidence, the gap between "scientific" and "entertainment" biological age testing will become stark. Only services that either buy a license for validated technology or retreat into the wellness niche will survive. Also losing is mainstream pharma, which bets on treating single diseases. SHARP offers a paradigm of "treat aging as a holistic process," where the endpoint is not HbA1c reduction but epigenetic rejuvenation.
What the Media Isn't Saying
All headlines focus on "slowing the biological clock." But almost no one noticed that SHARP's primary endpoint is not just epigenetic age, but epigenetic age measured using DNA methylation-based aging clocks. This means whole-genome methylation sequencing. The cost of one such test in a commercial lab is about $250–400. For 1,500 participants, that's at least $375,000 just for tests, not counting everything else: microbiome, proteomics, spirometry, EEG, menopause assessment.
Who pays for this? Sheba is a public hospital, but Strauss has openly stated she does not want to take money from patients and relies on grants and partnerships with tech companies. The question: if a partner provides an AI platform for free in exchange for data, can the results be considered independent? ClinicalTrials.gov does not require disclosure of institutional-level conflicts of interest. Formally, everything is clean. In reality, we are witnessing the creation of a reference dataset that one company can use to train and validate its models, while citing an "independent government study."
The second subtle point concerns compliance. The design assumes the intervention group receives personalized recommendations via an app and wearable device, while the control group receives only a baseline assessment and repeat tests. The problem is that people who pay $500 a year to participate in a longevity program are highly likely to change their behavior on their own, even if assigned to the control group. This is called contamination bias. If the intervention effect is statistically significant but small in magnitude, contamination will completely eat it. SHARP's design does not control for this.
Forecast: Next 30 Days and 90 Days
In the next 30 days, I expect Aisap.ai or a Sheba-affiliated entity to submit an application for Breakthrough Device Designation to the FDA for an AI-driven POCUS biological age clock. The validation publication on 243 SHARP participants already exists, the main trial protocol is registered—no formal barriers remain.
In the 90-day outlook, an institutional shift will occur. We will see at least one major US academic center—likely Mayo Clinic or Mass General Brigham—announce the launch of its own longevity research program, mirroring SHARP. Competition to define the "gold standard" for biological age assessment will enter an open phase. Simultaneously, the FDA will release a discussion paper on the status of epigenetic clocks as surrogate endpoints—not a guideline, but a signal to the market.
The main forecast: SHARP will become the case that changes the landscape of preventive medicine funding. When data from 1,500 participants shows a slowing of epigenetic age by 1.5–2 years over 12 months of intervention costing less than $2,000 per person, the Medicare Innovation Center will be forced to consider coverage for healthspan-oriented programs. The potential ROI is too large: each year of delayed institutionalization for an elderly patient saves $30,000–45,000. It is this economic argument, not enthusiasm for aging science, that will turn SHARP from a clinical trial into a precedent on which a new market worth over $10 billion will be built.
— Editorial Team
